Biovie Incis A Clinical Stage Biopharmaceutical Company Based In Carson Citynevadafounded In 2013The Company Focuses On Developing Innovative Drug Therapies For Neurological And Neurodegenerative Disordersas Well As Advanced Liver Diseasebiovie Was Previously Known As Nanoantibioticsincand Rebranded In July 2016 The Company Is Advancing Several Drug Candidatesincluding Biv201Which Is In Phase 3 Clinical Trials For Treating Ascites Due To Chronic Liver Cirrhosisanother Key Candidatene3107Bezisterim Is In Phase Iii Trials For Mild To Moderate Alzheimerae S Disease And Phase Ii Trials For Parkinsonae S Diseasene3107 Targets Neuroinflammation And Insulin Resistanceaiming To Improve Patient Outcomes Without Disrupting Essential Biological Functionsbiovie Incis Led By President And Ceo Cuong Viet Doalong With A Small Team Of 14 Employeesthe Company Is Publicly Traded On Nasdaq Under The Ticker Symbol Bivi
